1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

 
• By Dean Rudge

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
• Source: Shutterstock

Ahead of planned completion in June, German developer Formycon has published positive preliminary efficacy and safety data from its MAGELLAN-AMD Phase III clinical trial comparing the company’s proposed FYB203 aflibercept biosimilar to Regeneron’s Eylea (aflibercept) reference product.

Involving 434 participants, the randomized, double-masked, multicenter study is comparing the efficacy and safety of FYB203 to the world’s leading...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

‘We Will Be Everywhere’: Amneal On Biosimilar Vertical Integration And ‘Dead’ Licensing Deals

 
• By Urtė Fultinavičiūtė

Amneal continues to see biosimilars as an attractive but competitive space, with vertical integration in the US market being a key to its success.

The Power Of Data: BioPharmaSpec On Assessing Biosimilarity With Analytics

 
• By Urtė Fultinavičiūtė

With another regulator now considering the removal of clinical efficacy trials for biosimilars, BioPharmaSpec’s technical director Richard Easton paints the picture of data-powered biosimilarity assessment.

‘A True Biosimilar’: Amgen Links Amjevita’s Success To Quality And Regulatory Stability

 
• By Dean Rudge

Amgen’s CEO Robert Bradway has reaffirmed confidence in the company’s Humira biosimilar, Amjevita, as the company tackles with an ever-growing population of denosumab biosimilars.

‘Right Thing To Do’: Teva Feels Validated By Partner-Driven Biosimilar Approach

 
• By Dean Rudge

The FDA’s proposal to streamline clinical trials is seen as vindication for Teva’s partnership-driven biosimilar play, as the firm targets $400m in added sales by 2027.

More from Products

‘A True Biosimilar’: Amgen Links Amjevita’s Success To Quality And Regulatory Stability

 
• By Dean Rudge

Amgen’s CEO Robert Bradway has reaffirmed confidence in the company’s Humira biosimilar, Amjevita, as the company tackles with an ever-growing population of denosumab biosimilars.

‘Right Thing To Do’: Teva Feels Validated By Partner-Driven Biosimilar Approach

 
• By Dean Rudge

The FDA’s proposal to streamline clinical trials is seen as vindication for Teva’s partnership-driven biosimilar play, as the firm targets $400m in added sales by 2027.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.